# VISUAL III 👉🏼WHAT IS IT ? Long-term efficacy and safety of ADA in active or controlled noninfectious uveitis 👉🏼CONCLUSION * 60% of patients with active uveitis achieved quiescence at week 78, 66% of whom were corticosteroid free. * 74% of patients with inactive uveitis achieved quiescence at week 78, 93% of whom were corticosteroid free. * adverse events and serious adverse events were comparable to those in previous studies